Tedizolid phosphate is approved for the treatment of acute bacterial skin and skin structure infections in adults. We evaluated the pharmacokinetics of tedizolid in elderly subjects to guide dosing recommendations. In an open-label phase 1 study (ClinicalTrials.gov identifier NCT01496677), 14 elderly (≥65 years) and 14 younger control (18-45 years) subjects each received a single oral dose of tedizolid phosphate 200 mg. Blood samples were collected before dose and more than 72 hours after dose. The pharmacokinetic parameters of tedizolid after a single dose were similar in both age groups. Geometric mean ratios (elderly/younger controls) and corresponding 90% confidence intervals were maximum observed plasma concentration (C ), 1.091 (0.917-1.297); AUC from time 0 extrapolated to infinity (AUC ), 1.132 (0.954-1.343). Tedizolid plasma exposure was similar in elderly and younger control subjects. The findings indicated that after intravenous or oral administration of tedizolid phosphate 200 mg once daily, no dose adjustment was warranted in elderly subjects to achieve therapeutic levels.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cpdd.426 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetic/pharmacodynamic analysis of tedizolid phosphate against Staphylococcus aureus and Streptococcus pneumoniae in children, adolescents, and adults by Monte Carlo simulation.
J Glob Antimicrob Resist
November 2024
Department of Hematology, Tianjin First Central Hospital, Tianjin, PR China.
Objective: The objective of this study was to investigate the cumulative fraction of response of various dosage regimens of tedizolid phosphate against Staphylococcus aureus and Streptococcus pneumoniae in children, adolescents, and adults.
Methods: Monte Carlo simulations were performed using previously published pharmacokinetic parameters and pharmacodynamic data to evaluate the efficacy of the simulated dosage strategies in terms of area under the concentration-time curve/minimum inhibitory concentration targets of tedizolid.
Results: According to the results of the Monte Carlo simulations, currently approved dosage regimens of tedizolid phosphate were effective in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by methicillin-susceptible S.
In vitro and in vivo evaluation of tedizolid nanoparticle incorporated buccal films for oromucosal infections.
Int J Pharm
November 2024
Department of Biology, Science Faculty, Ege University, 35100 İzmir, Turkey; Laboratory Animals Research Center, Ege University, 35100 İzmir, Turkey.
Article Synopsis
- A novel formulation of tedizolid phosphate (TZP) nanoparticle-loaded buccal films was developed to treat buccal wounds infected with Staphylococcus aureus.
- The optimal nanoparticle (NP) formulation was characterized and incorporated into mucoadhesive buccal films, demonstrating effective antibacterial properties in both in vitro and in vivo studies.
- The study found that the TZP-NP-loaded films significantly reduced bacterial counts and effectively inhibited S. aureus growth in wound samples, indicating their potential for long-lasting antibacterial treatment of buccal wounds.
Tedizolid phosphate alleviates DSS-induced ulcerative colitis by inhibiting senescence of cell and colon tissue through activating AMPK signaling pathway.
Int Immunopharmacol
June 2024
School of Basic Medicine, Dali University, Dali 671000, Yunnan, China. Electronic address:
Article Synopsis
- Ulcerative colitis (UC) is an inflammatory bowel disease that may be worsened by cellular senescence, although their relationship is not fully understood.
- New research shows that the compound Tedizolid Phosphate (TED) can combat senescence in colon cells affected by the UC inducer dextran sulfate sodium (DSS).
- TED not only alleviated UC symptoms and colon senescence in mice but also worked by restoring AMPK signaling, suggesting that targeting senescence might be a promising treatment strategy for UC.
FDA-Approved Tedizolid Phosphate Prevents Cisplatin-Induced Hearing Loss Without Decreasing Its Anti-tumor Effect.
J Assoc Res Otolaryngol
June 2024
Medical Science and Technology Innovation Center, Shandong First Medical University, Jinan, 250117, China.
Purpose: Cisplatin is a low-cost clinical anti-tumor drug widely used to treat solid tumors. However, its use could damage cochlear hair cells, leading to irreversible hearing loss. Currently, there appears one drug approved in clinic only used for reducing ototoxicity associated with cisplatin in pediatric patients, which needs to further explore other candidate drugs.
View Article and Find Full Text PDFPoor removal of tedizolid during continuous hemodiafiltration: experiments using an in vitro continuous hemodiafiltration model.
J Pharm Health Care Sci
November 2023
Faculty of Pharmacy, Iryo Sosei University, 5-5-1 Iino, Chuo-Dai, Iwaki, Fukushima, 970-8551, Japan.
Background: Tedizolid is an oxazolidinone anti-MRSA drug with included in the National Health Insurance Drug Price List in 2018. The effect of hemodialysis on tedizolid phosphate concentrations has been reported; pre-dialysis concentrations decreased by 10% compared to post- dialysis concentrations. However, the material of the dialysis membrane remains unknown.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!